[ Pobierz całość w formacie PDF ]

New data from Phase III European clinical trials reinforce that
Wyeth's Prevenar 13 has the potential to guard against the 13 most
prevalent serotypes associated with pneumococcal disease. Release
Webinars
Register Today!
Events
Register today!
Register today
!
Marketplace
Click here.
opengenomics.com/pcr
.
Jobs
Learn more.
Learn more.
http://www.fiercepharma.com/jobs
.
FierceVaccines is a weekly update on the vaccine industry. Sign up
or learn more
 129
today.
XXIX.Evidence that the swine flu vaccine is planned to cause harm: Inclusion of adjuvants
Dr Ann Schuchat and Dr Tom Friedman said at CDC press conference --
http://www.cdc.gov/media/transcripts/2009/t090611.htm-- that adjuvants would be included in
the vaccine.
Squalene is an example of an organic adjuvant commonly used and has been blamed for some of
the tragic effects of the smallpox vaccine administered to Gulf War vets who developed the so-
called Gulf War Syndrome, which should be called the Fort Detrick Syndrome.
Adjuvants activate the pathogenes within a vaccine.
 In immunology, an adjuvant is an agent that may stimulate the immune system and increase the
response to a vaccine, without having any specific antigenic effect in itself.[1]The word
 adjuvant comes from the Latin word adjuvare, meaning to help or aid.[2]"An immunologic
adjuvant is defined as any substance that acts to accelerate, prolong, or enhance antigen-specific
immune responses when used in combination with specific vaccine antigens."[3]
Adjuvants have been called the dirty little secret of vaccines [4] in the scientific community,
because much about how adjuvants work is a mystery. Known adjuvants include oils, aluminum
salts, and virosomes. (Wikipeida)
 Anne Schuchat:Our HHS Secretary Sebelius announced May 22nd that nearly $1 billion was
going towards vaccine development and manufacturing. That included resources for the clinical
trials that are being carried out through NIH and through the manufacturers in collaboration, of
course, with the FDA and with the part of HHS that works on these pandemic matters. It also
included resources to assure manufacturing capacity for both antigen, the component of the
vaccine that gives you that immuno response, and the additional chemical that can sometimes
increase the immune response that's more specific to the antigen. So the actual amounts -- or I
can give you dollar figures rather than not ghost information -- there are five different
manufacturers that the HHS has contracted with and there's been a procurement order for a total of
$650 million worth of antigen, and $287 million worth of adjuvant. It is posh to say there are a lot
of steps important in the clinical development of a vaccine and the testing and we can't predict
today how much antigen would be needed. For the H1N1 vaccine we need a lot of antigen to get
the response but with adjuvant you could get a different response. We need to be able to
manufacture vaccine in case there is decision to use vaccine we have it on hand. Even if the
decision to use vaccine is not made, these orders permit the chemicals to be stored in bulk where
they could later be formulated if they needed to be. We've done this in a way that's giving us a lot
of options for the future.
Glen Nowak: Thank you, Anne.
Operator: Our next question comes from Alice Park with Time Magazine. Ma'am, your line is
open.
Alice Park: Yes, this is also a question about vaccines for either Dr. Schuchat or Dr. Frieden. At
this point do we have any better information for how well this vaccine is going to be matched to
whatever strain we might be in the fall, and how quickly would we be able to adjust this vaccine if
we were to see a slightly different variant of this H1N1 become more prevalent in the fall?
Glen Nowak: I'll have Dr. Schuchat answer that question.
Anne Schuchat:The good news so far is we have tested a number of isolates from around the
world, including different countries and many different states here in the U.S. Characteristics of
the virus are the same, suggesting that the strains that are being used for vaccine development are
matching the strains that are continuing to circulate. But with influenza, we need to keep looking.
 130
So we'll be testing strains through the course of the weeks and months ahead and learn more from
that about whether whatever may circulate here in the fall or winter is still the same as what has
been circulating so far. So at this point we have no reason to think that the strains that are being
used to develop vaccines have any kind of diversion from what's circulating. Now, of course
you've asked the question about how well will this work. That's the million dollar question
because we don't know yet. We're going to need to do those clinical studies to see whether a
vaccine that's developed gives a good immune reaction in different people, whether vaccine with
or without adjuvant and whether there are different doses people need to get a good response.
Those are studies we'll carry out over the next several months and we'll look forward to seeing
results from them.
There are reports that the flu vaccine contains squalene oil as an adjuvant.
Flu vaccine contains squalene oil as an adjuvant.
Micropaleontologist Dr. Viera Scheibner conducted research into the adverse effects of adjuvants
in vaccines and wrote: [3] Squalene  contributed to the cascade of reactions called  Gulf War
syndrome. GIs developed arthritis, fibromyalgia, lymphadenopathy, rashes, photosensitive rashes,
malar rashes, chronic fatigue, chronic headaches, abnormal body hair loss, non-healing skin
lesions, aphthous ulcers, dizziness, weakness, memory loss, seizures, mood changes,
neuropsychiatric problems, anti-thyroid effects, anaemia, elevated ESR (erythrocyte
sedimentation rate), systemic lupus erythematosus, multiple sclerosis, deadly Amyotrophic
Lateral Sclerosis, Raynaud s phenomenon with paroxysms of lack of blood in fingers and toes in
fingers and toes, Sjorgren s syndrome with blurred vision, chronic diarrhea, night sweats and low-
grade fever.
[4] Wikipedia A [5] study linking squalene, as experimental vaccine adjuvant, to individuals
with the clinical signs of Gulf War syndrome was published in 2002. A U.S. Federal Judge ruled
that there was good cause to believe aqualene to be harmful, and he ordered the Pentagon to stop
administering it in October 2004.
XXX. Conclusion
There is evidence that there is an international criminal corporate crime syndicate, directed by a
group called the Illuminati, are planning the mass murder of the people of the USA by using an
artificial virus as a pretext to deliver a toxic vaccinations.
There is clear, unambiguous evidence that Baxter is affiliated with this group and deliberately
released 72 kilos of pandemic material in February in Austria to trigger a pandemic in order to
justify a pandemic declaration level 6 by WHO and mass vaccinations.
There is evidence members of the same group were involved in engineering and releasing the
 swine flu virus in Mexico to allow WHO to declare pandemic level 6 on June 11th.
The same complex of international pharmaceutical companies and international government
agencies that have developed and released pandemic material have positioned themselves to profit
from triggering the pandemic by sealing contracts to supply the vaccine.
 131
There are reasonable grounds for believing that the mandatory vaccines will be purposely
contaminated with diseases that are specifically designed to cause death.
A fully licensed Novartis bird flu vaccine has killed at least 21 homeless people in Poland in the
summer of 2008 and had as its  primary outcome measure , an  adverse events rate , thereby
meeting the US government s own definition of a bioweapon (a biological agent designed to cause
an adverse events rate, i.e. death or injury) with a delivery system (injection). [ Pobierz całość w formacie PDF ]

zanotowane.pl

doc.pisz.pl

pdf.pisz.pl

razem.keep.pl